Luis E Rohde1, Neal A Chatterjee2, Muthiah Vaduganathan3, Brian Claggett3, Milton Packer4, Akshay S Desai3, Michael Zile5, Jean Rouleau6, Karl Swedberg7, Martin Lefkowitz8, Victor Shi8, John J V McMurray9, Scott D Solomon10. 1. Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; Hospital de Clínicas de Porto Alegre and Universidade Federal do Rio Grande do Sul Medical School, Porto Alegre, RS, Brazil. 2. Division of Cardiology, Department of Medicine, University of Washington, Seattle, Washington. 3. Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. 4. Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas. 5. Medical University of South Carolina and Ralph H. Johnson Veterans Affairs Medical Center, Charleston, South Carolina. 6. Institut de Cardiologie de Montréal, Université de Montreál, Montreál, Canada. 7. Department of Molecular and Clinical Medicine, University of Gothenburg, Sweden. 8. Novartis, East Hanover, New Jersey. 9. British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom. 10. Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. Electronic address: ssolomon@rics.bwh.harvard.edu.
Abstract
OBJECTIVES: The purpose of this study was to investigate the effect of sacubitril/valsartan therapy on sudden cardiac death (SCD) according to the use of and eligibility for an implantable cardioverter-defibrillator (ICD), stratified by heart failure cause. BACKGROUND: SCD still accounts for a significant proportion of overall mortality in heart failure with reduced ejection fraction (HFrEF). METHODS: Patients enrolled in the PARADIGM-HF (Prospective Comparison of ARNI with an ACE-Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial (n = 8,399) were evaluated to assess patterns of ICD implantation and eligibility according to clinical guidelines. The impact of ICD (adjusted for propensity of ICD implantation) and sacubitril/valsartan therapy on SCD was evaluated by using cause-specific Cox models and competing risk analysis. RESULTS: At baseline, of the 7,145 patients (85%) eligible for ICD implantation, only 1,243 (15%) had an ICD. Use of ICD varied by region with the highest rates in North America (56%) and lowest in Asia-Pacific (1.7%). In a propensity score-adjusted analysis, use of an ICD was associated with a 56% lower risk of SCD in ICD-eligible patients, in both patients with ischemic (p < 0.001) and nonischemic cardiomyopathy (p = 0.02). Sacubitril/valsartan reduced SCD risk in patients with an ICD (hazard ratio [HR]: 0.49; 95% confidence interval [CI]: 0.25 to 0.99) and in those who were eligible for but did not receive an ICD (HR: 0.81; 95% CI: 0.67 to 0.98). This effect was particularly evident in nonischemic cardiomyopathy (p < 0.05), although interaction with the cause of HF was not significant (p = 0.11 in subjects using an ICD and p = 0.25 in eligible nonusers). CONCLUSIONS: Use of an ICD was associated with lower rates of SCD, regardless of HF cause but was underused in most regions of the world in the PARADIGM-HF study. Sacubitril/valsartan reduced SCD risk regardless of use of an ICD or eligibility, particularly in ICD users and nonischemic cardiomyopathy.
OBJECTIVES: The purpose of this study was to investigate the effect of sacubitril/valsartan therapy on sudden cardiac death (SCD) according to the use of and eligibility for an implantable cardioverter-defibrillator (ICD), stratified by heart failure cause. BACKGROUND:SCD still accounts for a significant proportion of overall mortality in heart failure with reduced ejection fraction (HFrEF). METHODS:Patients enrolled in the PARADIGM-HF (Prospective Comparison of ARNI with an ACE-Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial (n = 8,399) were evaluated to assess patterns of ICD implantation and eligibility according to clinical guidelines. The impact of ICD (adjusted for propensity of ICD implantation) and sacubitril/valsartan therapy on SCD was evaluated by using cause-specific Cox models and competing risk analysis. RESULTS: At baseline, of the 7,145 patients (85%) eligible for ICD implantation, only 1,243 (15%) had an ICD. Use of ICD varied by region with the highest rates in North America (56%) and lowest in Asia-Pacific (1.7%). In a propensity score-adjusted analysis, use of an ICD was associated with a 56% lower risk of SCD in ICD-eligible patients, in both patients with ischemic (p < 0.001) and nonischemic cardiomyopathy (p = 0.02). Sacubitril/valsartan reduced SCD risk in patients with an ICD (hazard ratio [HR]: 0.49; 95% confidence interval [CI]: 0.25 to 0.99) and in those who were eligible for but did not receive an ICD (HR: 0.81; 95% CI: 0.67 to 0.98). This effect was particularly evident in nonischemic cardiomyopathy (p < 0.05), although interaction with the cause of HF was not significant (p = 0.11 in subjects using an ICD and p = 0.25 in eligible nonusers). CONCLUSIONS: Use of an ICD was associated with lower rates of SCD, regardless of HF cause but was underused in most regions of the world in the PARADIGM-HF study. Sacubitril/valsartan reduced SCD risk regardless of use of an ICD or eligibility, particularly in ICD users and nonischemic cardiomyopathy.
Authors: Santo Ricceri; James W Salazar; Andrew A Vu; Eric Vittinghoff; Ellen Moffatt; Zian H Tseng Journal: J Am Coll Cardiol Date: 2021-05-18 Impact factor: 24.094
Authors: Samaneh Salimian; Marc W Deyell; Jason G Andrade; Santabhanu Chakrabarti; Matthew T Bennett; Andrew D Krahn; Nathaniel M Hawkins Journal: Heart Rhythm O2 Date: 2021-12-17
Authors: Uwe Primessnig; Peter M Deißler; Paulina Wakula; Khai Liem Tran; Felix Hohendanner; Dirk von Lewinski; Florian Blaschke; Christoph Knosalla; Volkmar Falk; Burkert Pieske; Herko Grubitzsch; Frank R Heinzel Journal: Front Cardiovasc Med Date: 2022-07-05
Authors: Moritz Hadwiger; Nikolaos Dagres; Janina Haug; Michael Wolf; Ursula Marschall; Jan Tijssen; Alexander Katalinic; Fabian Simon Frielitz; Gerhard Hindricks Journal: Eur Heart J Date: 2022-07-14 Impact factor: 35.855